Share this @internewscast.com

The Food and Drug Administration may be one step closer toward what could be the first approval of a drug that uses the groundbreaking gene-editing tool CRISPR. 

The drug, called exa-cel, treats sickle cell disease, an inherited blood disorder that affects an estimated 100,000 people in the U.S., most of whom are Black, according to the Centers for Disease Control and Prevention. 

The illness causes the body’s red blood cells, usually disk-shaped, to take on a crescent or sickle shape. When this occurs, the cells can clump together, leading to clots and blockages in the blood vessels. This may result in a range of complications, including excruciating pain, trouble breathing or stroke.  

“The promise of a universally available, potentially curative option for individuals with sickle cell disease is revolutionary,” Dr. Biree Andemariam, hematologist and director of the New England Sickle Cell Institute at the University of Connecticut. Andemariam has consulted for Vertex Pharmaceuticals, which makes exa-cel. 

The illness is chronic and the only known cure is a bone marrow transplant from a donor, which carries the risk of rejection.

The gene-editing drug, from Vertex along with CRISPR Therapeutics, would eliminate the need for a donor. Instead, it works by changing the DNA in the patient’s blood cells.

Exa-cel uses CRISPR, a gene-editing tool that’s able to target certain stretches of DNA and snip them out, essentially deleting the unwanted section that, in the case of sickle cell disease, causes the cells to take on a crescent shape. 

On Tuesday, an FDA advisory committee reviewed the drug in an all-day meeting. These advisory meetings are usually one of the final steps before the agency decides whether to approve a drug. The FDA is expected to issue a final ruling by Dec. 8. 

No drug that uses CRISPR gene-editing — which was invented in 2009 — has been granted FDA approval. What’s more, Tuesday’s meeting looked different than past advisory committee meetings. In this case, the panel was not asked to evaluate the safety and effectiveness of Vertex’s drug, which is seeking approval for people age 12 and up with severe illness.

Instead, the focus was on the “off-target” effects of CRISPR — that is, when the technology makes cuts to other stretches of the DNA other than the intended target — and how the FDA should think about those risks moving forward.

It’s unclear what effects an off-target edit would have on a patient — it entirely depends on where it happens in the DNA. 

“Off-target editing does not necessarily mean that there’s going to be a bad outcome,” said committee member Scot Wolfe, a professor of molecular, cell and cancer biology at UMass Chan Medical School.

“There seems to be a lot of uncertainty, a lot of unknowns, about what these off-target changes might mean,” said committee member Lisa Lee, an epidemiologist and the director of scholarly integrity and research compliance at Virginia Polytechnic Institute and State University. 

“Are those unknowns more harmful than not allowing this to go forward?” Lee asked. 

Vertex Pharmaceuticals presented research findings on 46 people who received the treatment. Among the 30 patients with a minimum of 18 months of follow-up, 29 no longer experienced severe pain crises.

The company said there was no evidence of “off-target” effects from the therapy, but committee members questioned whether Vertex’s analysis was thorough enough.

“I’m not questioning that this product is important for our patients,” said committee member Dr. Joseph Wu, the director of the Stanford Cardiovascular Institute. “I’m just saying we’re at a point in which this thing is going to take off and wouldn’t it be nice to have more additional data.”

A big step forward but not a simple cure

Vertex has not disclosed the price of gene therapy but, if approved, it is expected to be extremely expensive, potentially costing as much as $2 million per patient, according to a report from the Institute for Clinical and Economic Review, a nonprofit group that helps determine fair prices for drugs. 

Dr. Stephan Grupp, chief of the therapy and transplant section of Children’s Hospital of Philadelphia, who consults for Vertex, said in an email that if approved, the step next would be to make sure patients can get access.

“I do think that they’re going to have to be a lot of questions answered regarding access,” Andemariam said.

While exa-cel is technically a one-time treatment, the process involves a number of steps. 

It starts by extracting stem cells from the patient’s blood. These stem cells are edited with exa-cel in the lab to delete the snippet of DNA that causes the cells to warp. Before these cells can be reinfused back into the patient, however, the patient must undergo chemotherapy to kill off cells that produce the sickle-shaped cells.

Follow NBC HEALTH on Twitter & Facebook.

Share this @internewscast.com
You May Also Like
Chicago Cubs set to take on San Diego Padres in first MLB playoff game at Wrigley Field since 2020

Chicago Cubs Gear Up to Face San Diego Padres in First Wrigley Field MLB Playoff Since 2020

CHICAGO (WLS) — It’s an exciting day on the city’s North Side.…
JSO: Teen killed in hit-and-run crash on Arlington Road

Jacksonville Sheriff’s Office: Teenager Dies in Arlington Road Hit-and-Run Accident

A pedestrian noticed a teenager lying unresponsive along Arlington Road North, according…
Retired mom among 3 killed in ‘premeditated’ North Carolina waterfront restaurant massacre

Tragic Waterfront Restaurant Attack in North Carolina: Retired Mom Among 3 Victims

One of the three people who lost their lives in the Saturday…
Gov. JB Pritzker, Chicago Mayor Brandon Johnson celebrate launch of Food Security for Life initiative at City Colleges

Governor JB Pritzker and Chicago Mayor Brandon Johnson Mark the Launch of the “Food Security for Life” Initiative at City Colleges

CHICAGO (WLS) — On Tuesday, Gov. JB Pritzker and Chicago Mayor Brandon…
Utah gov marks turning point as TPUSA returns after Charlie Kirk assassination

Utah Governor Marks Milestone as TPUSA Reunites Following Incident Involving Charlie Kirk

LOGAN, Utah – Turning Point USA returned to Utah Tuesday night for…
Eastwood Manor community in unincorporated McHenry County, Illinois is finally free of yellow water problem

Eastwood Manor Community in Unincorporated McHenry County, Illinois Resolves Yellow Water Issue

EASTWOOD MANOR, Ill. (WLS) — Residents in one north suburban community say…
Government shutdown begins as lawmakers fail to reach deal to extend funding

Government Shutdown Initiated After Lawmakers Fail to Secure Funding Agreement

Senate Majority Leader John Thune and Minority Leader Chuck Schumer debate government…
Teen Vogue Summit 2025 brings music, media, and powerful mentorship to young creators

The Teen Vogue Summit 2025 combines music, media, and inspiring mentorship for young creatives.

The 2025 Teen Vogue Summit took place in Los Angeles, where it…
Strong earthquake kills 31 people in a central Philippine region hit by deadly storm just days ago

Powerful earthquake claims 31 lives in central Philippine region recently ravaged by a deadly storm

MANILA, Philippines — A 6.9 magnitude earthquake struck offshore in the central…
ICE in Chicago protest: Broadview, Illinois leaders to address what they call 'unprovoked' use of chemical agents at ICE facility

Chicago ICE Protest: Broadview, Illinois Leaders Condemn Alleged ‘Unprovoked’ Use of Chemical Agents at ICE Facility

CHICAGO (WLS) — Officials from the village of Broadview are scheduled to…
Travel warning: Delta Air Lines credit card policy nearly strands couple in London, England | What to know

Travel Alert: Delta Air Lines Credit Card Policy Almost Leaves Couple Stuck in London, England | Essential Information

PHILADELPHIA — There is an important alert for airline travelers. In addition…
A Right Delayed Is a Right Denied: DOJ Suing LA County for Slow-Walking CCW Apps

Justice Delayed Is Justice Denied: DOJ Takes Legal Action Against LA County for Slow Processing of Concealed Carry Permit Applications

The Trump administration’s Justice Department is taking legal action against the Los…